The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity medications. Amid growing demand for such treatments, significant advancements in drug development are increasingly focused on long-term sustainability and safety to meet the needs of individuals struggling with weight maintenance.Eli Lilly and Co (NYSE:LLY) on Thursday shared topline results from the ATTAIN-MAINTAIN Ph ...

Key Takeaways NVO is pursuing approval for Wegovy 7.2 mg to counter slowing sales amid rising GLP-1 competition.STEP UP showed Wegovy 7.2 mg delivered 20.7% average weight loss vs 17.5% with the 2.4 mg dose.NVO has filed for the approval of Wegovy 7.2 mg in the U.S. and EU, with decisions expected in 2026.Novo Nordisk (NVO) is a leading player in the obesity market, driven by its blockbuster GLP-1 therapy Wegovy (semaglutide). However, despite being a core growth driver, Wegovy’s sales momentum has slowed i ...

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund focuses on owning a concentrated portfolio of U.S. large-cap stocks. For the third quarter of 2025, the fund reported a net return of 7.46% outperforming its benchmark, the Russell 1000 Value Index, which returned 5.33% for the same period. During the quarter, the portfolio reduced its weight in the IT sector to increase ho ...

Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity. https://t.co/XJjvikIDWU ...

Core Viewpoint - Novo Nordisk has filed for U.S. FDA approval of CagriSema, a once-weekly injection designed to treat obesity by combining two compounds [1] Company Summary - CagriSema represents a new treatment option in the obesity market, potentially expanding Novo Nordisk's portfolio in this growing sector [1] Industry Summary - The obesity treatment market is experiencing significant growth, and the introduction of CagriSema could enhance competition among pharmaceutical companies [1]

抢占诺和诺德存量市场 礼来公司旗下在研口服减肥药orforglipron在最新后期临床试验中取得关键进展，证明其能够有效帮助从 针剂转药的患者维持减重效果。鉴于该药物所展现的临床潜力，礼来周四宣布已向美国食品药品监督管 理局（FDA）提交了该每日一次GLP-1口服药的上市申请，旨在为肥胖症患者提供无需注射的长期体重 管理方案。 最新的临床数据显示，患者在从礼来的Zepbound或诺和诺德的Wegovy注射剂切换至orforglipron口服药 后，能够维持绝大部分减重成果。这一结果解决了肥胖治疗领域的一个核心痛点，即患者在停止每周一 次的针剂注射后往往会出现体重明显反弹。 受此便利性优势驱动，口服减重药物被视为该领域下一个突破点。FDA已在11月向礼来授予了优先审评 凭证，这意味着该药的审核周期可能缩短至数月内。尽管礼来的口服药在总体减重幅度上可能略逊于现 有的针剂，但其作为"无针化"维持治疗方案的潜力，正成为市场关注的焦点。 目前，全球减重药市场正演变为礼来与诺和诺德的两强争霸。虽然诺和诺德的口服版Wegovy预计将率 先上市并抢占先机，但礼来通过orforglipron展示了从竞争对手手中夺取维持期患者市 ...

In this article, we will look at the 10 Best Non-US Stocks to Buy According to Hedge Funds.On December 9, Michelle Gibley, Director of International Equity Research and Strategy at the Schwab Center for Financial Research, released her 2026 Outlook for International Stocks and Economy. She sees international markets as well-positioned for another strong year, driven by robust earnings, economic growth, and attractive valuations compared to the S&P 500. Gibley notes 2026 to be the year of broadening out and ...

Novo Nordisk has halted the development of any drug not tied to diabetes or obesity. That narrower focus is meant to clear the way for two new launches next year, including an oral version of Wegovy https://t.co/w64rYoowC4 ...

礼来公司周四表示，在一项后期临床试验中，其备受关注的减肥药片帮助患者在直接从该公司注射剂 Zepbound或诺和诺德（Novo Nordisk）竞品注射剂Wegovy转换用药后，维持了大部分减重成果。 该公司还表示，已向美国食品药品监督管理局（FDA）提交了每日一次的GLP-1类减肥药片orforglipron 的上市申请。FDA在11月表示，已授予该药片优先审评券，可能将其审评时间缩短至数月。 积极的试验数据表明，对于希望保持减重效果但不愿长期接受每周注射的患者而言，该药片可能是一种 有效的过渡治疗选择。许多停止注射的人会重新增加大部分最初减掉的体重。 尽管礼来公司的药片整体减重效果似乎不如现有注射剂，但周四的结果凸显了其作为无针维持疗法在重 磅GLP-1市场中的潜力。然而，诺和诺德的口服减肥药可能会率先上市，使这家丹麦制药商在该领域占 据先机。 这项三期试验追踪了300多名肥胖患者，他们此前在另一项后期研究中接受了72周的Wegovy或Zepbound 治疗。随后，这些患者被随机分配继续服用礼来的药片或安慰剂，为期52周。在那些此前使用注射剂时 减重效果进入平台期的患者中，该口服药物达到了试验主要目标，即 ...

Key Points Novo Nordisk's new indications for semaglutide and its attractive pipeline could allow it to bounce back. Intuitive Surgical should remain the leader in its niche despite increased competition. Both stocks could be long-term winners, and the choice today might depend on risk tolerance. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) and Intuitive Surgical (NASDAQ: ISRG) are both healthcare leaders, but they operate in different corners of this vast sector. The for ...